Douglas Miehm
Stock Analyst at RBC Capital
(2.15)
# 2,789
Out of 4,761 analysts
45
Total ratings
47.06%
Success rate
-5.11%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb | Maintains: Outperform | $22 → $18 | $15.75 | +14.29% | 12 | Feb 20, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $11 → $10 | $7.31 | +36.80% | 19 | Jan 30, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $141 → $143 | $120.67 | +18.51% | 5 | Dec 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $13 → $8 | $7.93 | +0.88% | 9 | Feb 16, 2024 |
Bausch + Lomb
Feb 20, 2025
Maintains: Outperform
Price Target: $22 → $18
Current: $15.75
Upside: +14.29%
Bausch Health Companies
Jan 30, 2025
Maintains: Sector Perform
Price Target: $11 → $10
Current: $7.31
Upside: +36.80%
Ligand Pharmaceuticals
Dec 11, 2024
Maintains: Outperform
Price Target: $141 → $143
Current: $120.67
Upside: +18.51%
Aurinia Pharmaceuticals
Feb 16, 2024
Maintains: Outperform
Price Target: $13 → $8
Current: $7.93
Upside: +0.88%